Michel P Hermans1*, Jean-Charles Fruchart2, Jean Davignon3, Khalid Al-Rubeaan4, Pierre Amarenco5, Gerd Assmann6, Philip Barter7, John Betteridge8, Eric Bruckert9, M John Chapman10, Ada Cuevas11, Michel Farnier12, Ele Ferrannini13, Paola Fioretto14, Jacques Genest15, Henry N Ginsberg16, Antonio M Gotto Jr17, Dayi Hu18, Takashi Kadowaki19, Tatsuhiko Kodama20, Michel Krempf21, Yuji Matsuzawa22, Jesús Millán Núñez-Cortés23, Carlos Calvo Monfil24, Hisao Ogawa25, Jorge Plutzky26, Daniel J Rader27, Željko Reiner28, Shaukat Sadikot29, Raul D Santos30, Evgeny Shlyakhto31, Piyamitr Sritara32, Rody Sy33, Alan Tall34, Chee-Eng Tan35, Lale Tokgözoglu36, Peter P Toth37, Paul Valensi38, Christoph Wanner39, Alberto Zambon14, JunRen Zhu40and Paul Zimmet41
Received date: July 22, 2014; Accepted date: August 11, 2014; Published date: August 19, 2014
Citation: Hermans MP, Fruchart JC, Davignon J, Al-Rubeaan K, Amarenco P, et al. (2014) Residual Microvascular Risk in Type 2 Diabetes in 2014: Is it Time for a Re-Think? A Perspective from the Residual Risk Reduction Initiative (R3i). J Diabetes Metab 5:413. doi: 10.4172/2155-6156.1000413
Copyright: © 2014 Hermans MP, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Visit for more related articles at Journal of Diabetes & Metabolism
Microvascular complications associated with type 2 diabetes, including diabetic retinopathy, nephropathy and neuropathy, account for much of the societal burden of diabetes. Even with effective multifactorial intervention, targeting glycemia, blood pressure and lowdensity lipoprotein cholesterol, in addition to lifestyle intervention, a high residual microvascular risk persists. The Residual Risk Reduction Initiative (R3i) highlights two key priorities for reducing this residual risk. First, there should be optimal management of cardiometabolic risk factors, including atherogenic dyslipidemia, elevated triglycerides and low plasma high-density lipoprotein cholesterol, to improve lipid goal attainment. Second, consistent evidence from two major trials may merit consideration of adjunctive fenofibrate therapy to slow progression of diabetic retinopathy in type 2 diabetes patients with pre-existing disease. These data provide a strong rationale for testing in a prospective study. The R3i strongly believes that addressing both priorities is critical to reducing the substantial residual risk of microvascular complications in type 2 diabetes.
Microvascular residual risk; Type 2 diabetes; Diabetic retinopathy; Diabetic nephropathy; Atherogenic dyslipidemia; Prevention; Guidelines
Diabetes mellitus poses one of the most important health challenges in the 21st century. Based on latest estimates, globally more than 382 million people have diabetes, predominantly type 2 diabetes, and by 2035 this will have risen to 592 million . The greatest escalation in diabetes prevalence has been in developing regions, and as a consequence, it is anticipated that the future burden of diabetes will be greatest there .
Much of the focus of clinical management in type 2 diabetes has been on prevention of cardiovascular complications from macroangiopathies. However, recent data from the Global Burden of Disease 2010 highlight the importance of diabetes-related microvascular complications, including diabetic retinopathy and nephropathy, responsible for more than 50% of the burden of disability associated with diabetes . About one in three people with type 2 diabetes have clinical signs of diabetic retinopathy or diabetic kidney disease, and an even larger proportion has silent or clinical peripheral (lower-limb) sensory neuropathy [1,3,4]. Indeed, diabetic retinopathy is the leading cause of vision loss in adults of working age (20 to 65 years) in industrialized countries . Although the cost of managing such complications is initially relatively low (especially when compared with the diagnostic and therapeutic costs of macroangiopathies), progression to more advanced stages, i.e., visual loss, end-stage renal disease and lower-extremity amputation substantially increases this. Estimates suggest that the presence of microvascular complications almost doubles management costs compared with patients without these complications . Together, the escalation in diabetes prevalence and increasing longevity of people with diabetes due to improved management of cardiometabolic risk factors, will undoubtedly contribute to a further substantial increase in the socioeconomic burden associated with chronic diabetes-related microvascular complications . As an example from the US, costs associated with managing diabetes-related complications have nearly doubled over the last 5 years, despite improvements in general care. Given finite healthcare resources, this is an urgent issue warranting action .
Effective multifactorial intervention, targeting glycaemia, blood pressure and Low-Density Lipoprotein (LDL) cholesterol, is clearly important for preventing or delaying progression of macro- and microvascular complications. Yet even with optimal management, such complications continue to develop or progress. Five years ago, the Residual Risk Reduction Initiative (R3i) highlighted this issue, clearly illustrated by the STENO-2 study [8-10]. Multifactorial intervention, including tight glycemic regulation, blood pressure control and the use of renin–angiotensin system blockers, aspirin and statins, in addition to lifestyle intervention, reduced the risk of macroangiopathies and major diabetes-related complications (retinopathy and nephropathy), but was insufficient to completely prevent the development or progression of microvascular disease in up to 50% of patients with type 2 diabetes (Figure 1) [9,10]. While it is acknowledged that few patients achieved all three targets for blood glucose, blood pressure and LDL cholesterol, STENO-2 still showed the high residual risk of microvascular complications that persists in diabetes patients.
Figure 1: As highlighted by the R3i, the STENO-2 study showed that intensive multifactorial intervention delayed but did not prevent the development or progression of diabetic-related microvascular complications in persons with type 2 diabetes. Data presented as relative risk (RR) with 95% confidence intervals. Reproduced with permission from Fruchart JC et al.  RR relative risk. Diabetic nephropathy was defined as urinary albumin excretion of >300 mg per 24 hours in 2 of 3 sterile urine specimens. Diabetic retinopathy was graded according to the 6-level grading scale of the European Community-funded Concerted Action Programme into the Epidemiology and Prevention of Diabetes by 2 independent ophthalmologists, who were unaware of treatment assignment. Peripheral neuropathy was measured with a biothesiometer and autonomic neuropathy was diagnosed based on measurement of the RR interval on an ECG during paced breathing and an orthostatichypotension test conducted by a laboratory technician who was unaware of the patients’ treatment assignment.
Subsequent investigations focused on a key question: Does intensification of glycemic or blood pressure control reduce this high residual risk of diabetes-related microvascular complications? The rationale for such approaches was suggested by data from the United Kingdom Prospective Diabetes Study (UKPDS), which showed improved benefit, especially for retinopathy, with prolonged improvement in glycemic control in newly-diagnosed type 2 diabetes patients (Table 1) [11,12].
|Trial[follow-up]||N||Intervention||Outcome measure||Relative RR||Absolute RR||NNT||p-value|
|ACCORD-EYE [4 years]||2,856||Intensive vs. standard glycemic control||Progression ≥3 steps of ETDRS, laser photocoagulation or vitrectomy||37%||3.1%||32||0.003|
|1,263||Intensive vs. standard BP control||23%||-1.6%||- 62||0.29|
|ADVANCE [15,19] [5 years]||11,140||Intensive glycemic control||New or worsening retinopathy||5%||0.3%||333||NR|
|[4.3 years]||Intensive vs. standard BP control||1%||-0.1%||-100||NR|
|VADT (14)[5.6 years]||1,791||Intensive vs. standard glycemic control||Progression ≥2 steps of ETDRS||23%||5.1%||19||0.07|
|UKPDS* [11,12][Up to 12 years]||3,867||Intensive vs. standard glycemic control||2-step progression of ETDRS Retinal photocoagulation||21%29%||10.1%2.7%||1037||0.0150.003|
|1,148||Intensive vs. standard BP control||2-step progression of ETDRS Retinal photocoagulation||34%35%||17.3%4.0%||625||0.00380.023|
|ACCORD [5 years]||10,251||Intensive vs. standard glycemic control||New-onset microalbuminuriaNew-onset macroalbuminuria||15%29%||3.1%1.7%||3258||0.00120.0003|
|ADVANCE [15,19][5 years]||11,140||Intensive vs. standard glycemic control||New or worsening nephropathyNew onset microalbuminuria||21%9%||1.1%2.0%||9150||0.0060.02|
|[4.3 years]||Combination BP vs. standard control||New or worsening nephropathyNew onset microalbuminuria||18%21%||0.6%4%||16725||0.055<0.0001|
|VADT [5.6 years]||1,791||Intensive vs. standard glycemic control||Any increase in albuminuria Progression to macroalbuminuria||34%43%||4.7%2.2%||2145||0.030.04|
|UKPDS* [11,12][Up to 15 years]||3,867||Intensive vs. standard glycemic control||Microalbuminuria||30% at 15 yr||11.9% at 15 yr||8||0.033|
|[Up to 9 years]||1,148||Intensive vs. standard BP control||Urinary albumin ≥50 mg/L||29% at 6 yr13% at 9 yr||8.2% at 6 yr4.3% at 9 yr||1223||0.00850.33|
Table 1: Effect of intensification of glucose or blood pressure control on progression of diabetic microvascular complications in type 2 diabetes patients, contd.
With respect to improved glycemic control, the Action to Control Cardiovascular Risk-Eye (ACCORD-Eye) study showed that targeting euglycemia (i.e. HbA1c<6% [42 mmol/mol] as a surrogate marker) in persons with long-standing type 2 diabetes significantly slowed the progression of diabetic retinopathy, defined by ≥ 3 steps worsening of the Early Treatment Diabetic Retinopathy Study (ETDRS) scale, or the development of proliferative retinopathy requiring laser treatment or vitrectomy (absolute reduction from 10.4% to 7.3%, relative risk reduction [RRR] 37%, p=0.003) (Table 1) . Similar findings were reported by the Veterans Administration Diabetes Trial (VADT) , although the Action in Diabetes and Vascular disease: preterAx and diamicroN-MR Controlled Evaluation (ADVANCE) study showed no benefit [14,15]. Intensive glycemic control also favorably impacted certain intermediate renal outcomes, including new-onset microand macroalbuminuria in ACCORD, and new-onset or worsening albuminuria in ADVANCE and VADT, although the absolute benefit was less than that previously documented in newly-diagnosed patients in the UKPDS (Table 1) [12,14-16]. However, these findings need to be considered against the overall risks of glucose-lowering treatment. In ACCORD there was an increase in all-cause mortality in patients allocated to the intensive glucose-lowering arm . More recently, the ORIGIN (Outcome Reduction with an Initial Glargine Intervention) study showed that early use of basal insulin to target normal fasting plasma glucose levels did not impact cardiovascular outcomes . Both the ACCORD and ORIGIN studies also showed an increased risk of hypoglycemia and weight gain, detrimental for the management of patients with type 2 diabetes [17,18]. Furthermore, practical limitations relating to the likelihood of achieving normal or near-normal HbA1c should not be understated. Taken together, the implications of these data are that targeting a near-normal HbA1c value with currently available glucose-lowering therapies is not appropriate in high-risk patients with long-standing type 2 diabetes.
Improved blood pressure control was shown to reduce the development or progression of albuminuria in ADVANCE, although there was little benefit on diabetic retinopathy beyond that observed with conventional control  (Table 1). The ADVANCE retinal substudy showed a trend towards reduction in the risk of progression of retinopathy with combination blood pressure lowering treatment, although the difference versus standard therapy was not statistically significant (odds ratio 0.78, 95% CI 0.57-1.06, p=0.12) .
Angiotensin-receptor blockade has shown class-specific benefits on microangiopathies. In the Renin–Angiotensin System Study (RASS), treatment with either enalapril or losartan reduced progression of diabetic retinopathy by 65% (p=0.02) and 70% (p=0.008), respectively . Furthermore, in the DIRECT (Diabetic REtinopathy Candesartan Trials) program, treatment with candesartan reduced diabetic retinopathy in patients with type 1 diabetes (by 26%, p=0.046) . While there was evidence of regression of diabetic retinopathy in patients with type 2 diabetes, there was no significant benefit of treatment on retinal disease progression (the primary endpoint of the study) [22,23]. In addition, in the Randomized Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) trial, olmesartan delayed the onset of microalbuminuria in type 2 diabetes patients with coronary artery disease and normoalbuminuria . However, it should be noted that blood pressure control was similar in patients irrespective of the addition of olmesartan to conventional antihypertensive therapy, with 80% in the olmesartan group versus 71% of the placebo group achieving target blood pressure (<130/80 mmHg). Furthermore, an excess of cardiovascular deaths in the olmesartan group was a concern. Thus, blood pressure lowering mediated via renin-angiotensin blockade is associated with renal protection in patients with type 2 diabetes, although the ACCORD blood pressure trial did suggest limitations with aggressive blood pressure lowering beyond that currently recommended by guidelines .
Finally, there is no evidence to date that further lowering of LDL cholesterol beyond desired levels benefits diabetic retinopathy . Furthermore, the potential benefits of intensive LDL cholesterol lowering with high-dose statins need to be weighed against the known increase in risk of incident diabetes associated with this treatment, especially in patients with established risk factors for diabetes, or the potential to worsen glycemic control in patients already diagnosed with diabetes .
A role for atherogenic dyslipidemia?
Taken together, perhaps the main message from recent trials is to optimize control of conventional vascular risk factors to reduce the residual risk of diabetes-related microvascular complications. In this context, consideration of atherogenic dyslipidemia, the combination of elevated triglycerides – a marker of triglyceride-rich apolipoprotein B-containing lipoproteins – and low plasma concentration of High- Density Lipoprotein (HDL) cholesterol may be relevant. The R3i has already highlighted atherogenic dyslipidemia as an important contributor to lipid-related residual macrovascular risk, and, potentially, to the risk of diabetic microvascular complications in persons receiving best standards of care for prevention of cardiovascular disease, including high-dose statins [8,28-30].
Recent studies provide a rationale for therapeutic targeting of atherogenic dyslipidemia. The Verona Diabetes Study a longitudinal, observational study in type 2 diabetes outpatients (n=979), highlighted the relevance of the fasting triglycerides/HDL cholesterol ratio (TG/ HDL-C) to the risk of developing diabetic retinopathy or nephropathy . Over a mean 4.9 year follow-up period, each one standard deviation increase in log TG/HDL-C more than doubled the risk of retinopathy and/or chronic kidney disease (odds ratio 2.15, 95% CI 1.09-4.25, p=0.02); the increase in risk was even higher for chronic kidney disease alone (odds ratio 4.65, 95% CI 1.50-14.90, p=0.02). This association was independent of confounding factors including HbA1c, blood pressure, LDL cholesterol, albuminuria, diabetes duration and body mass index. The prognostic significance of an elevated log TG/HDL-C ratio was even more pronounced in patients with well controlled LDL cholesterol levels (<100 mg/dL). In a systematic review, elevated triglycerides were predictive of the onset or progression of nephropathy in patients with type 2 diabetes . Additionally, post hoc analyses from ADVANCE highlighted low HDL cholesterol (<43 mg/dL) as a prognostic factor for the development of diabetic-related renal events, in particular newonset albuminuria . There was, however, no association between low HDL cholesterol and risk for diabetic retinopathy. This is perhaps not surprising given the multiple pathways implicated in the underlying pathogenesis of this complication .
Most recently, the evidence-base for a role for atherogenic dyslipidemia has been strengthened by the REALIST (REsiduAl risk Lipids and Standard Therapies) microvascular study . This crosssectional case-control study included 2,535 type 2 diabetes patients with either diabetic kidney disease (n=1891), diabetic retinopathy (n=1,218) or both complications (n=574), and 3,683 matched controls, enrolled by 24 sites in 13 countries in Europe, North America, the Middle East, Asia (including Japan and China), and Australasia. REALIST-Micro showed that both elevated triglycerides and low HDL cholesterol were significantly and independently associated with diabetic microvascular complications, specifically diabetic kidney disease; the association was less robust for diabetic retinopathy. These associations persisted after adjustment for blood pressure and HbA1c (Table 2). Despite the limitations inherent with a cross-sectional design, heterogeneity with respect to lipid measurement across the centers and the potential for reverse causation, this study is supportive of the rationale for targeting atherogenic dyslipidemia to reduce the residual diabetic renal disease risk.
|Hazard ratio (95% CI)|
|Any microvascular complication|
|Each ↑ by 44 mg/dL in TG||1.16 (1.11-1.22)|
|Each ↑ 8 mg/dL in HDL-C||0.92 (0.88-0.96)|
|Diabetic kidney disease|
|Each ↑by ~45 mg/dL in TG||1.23 (1.16-1.31)|
|Each ↑ 8 mg/dL in HDL-C||0.86 (0.82-0.91)|
|Each ↑ by ~45 mg/dL in TG||1.09 (1.02-1.16)*|
|Each ↑ 8 mg/dL in HDL-C||0.93 (0.86-1.0)*|
Table 2: REALIST-Micro: association of triglycerides (TG) and HDL cholesterol with risk for diabetic kidney disease and/or diabetic retinopathy. Data from Sacks et al. .
There are so far limited data relating to the potential association between atherogenic dyslipidemia and diabetic neuropathy. A small study has implicated elevated triglycerides with diabetic neuropathy, a causative factor in lower-extremity amputations [36,37]. Hypertriglyceridemia was also an independent risk factor for lower extremity amputation in a large cohort of patients with diabetes (n = 28,701) within a US health claims database .
Taken together, the available data suggest a rationale for targeting atherogenic dyslipidemia, in addition to best standards of care, to reduce the residual risk of diabetic microvascular complications in patients with type 2 diabetes. Indeed, a recent observational cohort study of the US HealthCore Integrated Research Database (n=72,267) provides evidence to support the value of targeting guideline-recommended levels for non-HDL cholesterol, HDL cholesterol and triglycerides in patients with newly-diagnosed type 2 diabetes. Compared with patients who did not meet these levels, those who attained desirable levels for HDL cholesterol (>40 mg/dL for men and >50 mg/dL for women) or triglycerides (<150 mg/dL) had an 11% and 15% lower risk, respectively, of diabetic microvascular events (diabetic neuropathy, retinopathy, and nephropathy, p <0.0001 for each analysis) (Figure 2) . However, due to the inherent limitations of this study design these findings should be viewed as hypothesis-generating and thus require testing in a randomized controlled trial.
Figure 2: Lipid goal management and reduction in microvascular events in Attainment of lipid goals for high-density lipoprotein (HDL) cholesterol, triglycerides and non-HDL cholesterol reduced the risk of diabetic complications (retinopathy, nephropathy or neuropathy, all p< 0.0001). Data from Toth et al. * Adjusted multivariate Cox regression analysis for patients at lipid goal versus those who did not achieve lipid goal.Lipid goals were defined according to the current American Diabetes Association guidelines; HDL cholesterol >40 mg/dL in men and >50 mg/dL in women and triglycerides < 150 mg/dL.
Reducing residual microvascular risk
Clinical evidence for PPAR agonists: There is currently limited evidence for therapeutic strategies that reduce residual microvascular risk. The best evidence to date implicates a role for Peroxisome Proliferator Activated-Receptor (PPAR) agonists, with the most extensive data with fenofibrate, both for slowing progression of diabetic retinopathy and slowing progression of microalbuminuria (Table 3) [13,40-43]. Indeed, consistent evidence from two major prospective placebo-controlled studies - the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) and ACCORD-Eye studies - that fenofibrate treatment delays progression of early diabetic retinopathy by 30-40% in type 2 diabetes patients with pre-existing disease, supported recent approval of fenofibrate as an adjunctive treatment to slow the progression of early-stage diabetic retinopathy in Australia (November, 2013). This clearly represents a major development for the management of diabetic eye disease. There are also data suggesting reduction in the risk of first minor lower-limb amputation associated with fenofibrate treatment in the FIELD study, although it is acknowledged that the etiology of diabetes-related amputation is complex, with neuropathy, macrovascular and microvascular disease all playing a role .
|Study||Microvascular outcome||Relative RR||Absolute RR||NNT||p-value|
|First laser treatment for retinopathy||31%||1.5%||67||0.002|
|i) DR progression, i.e. ≥2 steps of the ETDRS,macular edema or laser treatment
ii) ≥2 steps of the ETDRS
No pre-existing retinopathy
|DR progression, i.e. ≥3 steps of the ETDRS or proliferative DR requiring laser therapy or vitrectomy||40%||3.7%||27||0.006|
Table 3: Effects of fenofibrate on Diabetic Retinopathy (DR) progression: Summary of results from the FIELD and ACCORD-Eye studies [13,41].
However, there remain a number of unanswered questions. First, are these effects specific to fenofibrate or do they relate to fibrates more generally? Indeed, findings from a recent study in a real-world setting (n=5,038 type 2 diabetes patients) indicate that fibrate treatment (including bezafibrate, fenofibrate, ciprofibrate or gemfibrozil) was independently associated with reduction in progression to first retinopathy (primary outcome) . Both bezafibrate (n=1739) and fenofibrate (n=1413) were the most commonly prescribed fibrates in this study (for a mean of 2.1 and 2.8 years, respectively). However, with the limitations of a retrospective real-world data analysis, it is not possible to differentiate the effects of specific fibrates. Investigation of potential differential effects depending on the profile (alpha, gamma and/or delta), selectivity and potency of PPAR agonism at comparable doses is clearly warranted .
The other key question relates to the underlying mechanism(s), in particular for effects on diabetic retinopathy progression. While fibrates improve the underlying lipids and lipoproteins abnormalities associated with elevated triglycerides, decreased HDL number or functionality, and low plasma concentration of HDL cholesterol, the pathophysiological link between diabetic retinopathy and atherogenic dyslipidemia is tenuous. Indeed, in both the FIELD and ACCORD-Eye studies, there was no association between the lipoprotein- and lipidmodifying effects of fenofibrate and incidence or progression of diabetic retinopathy [13,40,41]. Recent insights suggest that both lipid-mediated as well as non-lipid mechanisms may be implicated . These may include systemic effects mediated by upregulation of apolipoprotein A-I (apoA-I, the main apolipoprotein in HDL), as suggested by small, single center studies, as well as local or systemic changes influencing intraretinal lipid transport [48,49]. Furthermore, whether effects on the qualitative properties of lipoproteins play a role is not known, although it is likely that the recognized pleiotropic effects of fibrates, including antioxidant, anti-inflammatory and anti-apoptotic properties, and improvement of endothelial function are perhaps more relevant, as previously discussed by Simo et al. .
As with all treatments, risk versus benefit considerations is merited. Fenofibrate is known to increase serum creatinine, which may prompt questions about its wider use in type 2 diabetes patients who often have some degree of renal impairment. In ACCORD Lipid, an increase in serum creatinine (defined as ≥ 20% increase from pre-treatment levels) was reported for nearly one-half (48%) of patients with longstanding type 2 diabetes within 3 months of starting fenofibrate treatment (versus 9% of the placebo group). Of these patients, about one-quarter subsequently received a reduced dose of fenofibrate, and about one-third stopped study treatment . However, in both the FIELD and ACCORD Lipid studies the increase in serum creatinine was transient and reversible within 6-8 weeks [40,51,52]. Furthermore, subsequent analyses showed that the increase in serum creatinine in fenofibrate-treated patients was unexpectedly associated with slower (rather than higher) secular loss of renal function. Over the course of the 5-year follow-up in the FIELD study, the decline in estimated glomerular filtration rate (eGFR) was reduced by 73% with fenofibrate compared with placebo . Additionally, in the Renal Ancillary study of ACCORD Lipid, among patients in the fenofibrate treatment group who were chosen because they did not show any increase in serum creatinine (≤ 2% change from pre-treatment levels), mean eGFR at the end of study was higher compared with those in the placebo group (81.8 versus 77.8 mL/min/1.73 m2), raising the possibility that there was net preservation of renal function over time in this group . Further, the fenofibrate-associated increase in serum creatinine did not appear to detrimentally impact cardiovascular risk, as indicated by a post hoc subgroup analysis of the FIELD study. While patients in the placebo group of this study with moderate renal impairment had the highest cardiovascular event rates, fenofibrate treatment was associated with a relative reduction in cardiovascular risk of 32% versus 15% in patients with normal renal function . Admittedly, this analysis was based on a limited sample (~5% of the total study population), and the use of the Modification of Diet in Renal Disease formula in FIELD may have underestimated eGFR. Despite these caveats, these data may help to reassure clinicians who may be considering the use of adjunctive fenofibrate therapy in type 2 diabetes patients.
Evidence for other approaches: Evidence for other therapeutic approaches is limited. There may be a rationale for investigating the potential of omega-3 fatty acids, given experimental data showing favorable effects on key mechanisms implicated in the vasodegenerative phase of diabetic retinopathy, and preservation of retinal function in animal models of type 2 diabetes mellitus [54,55]. Additionally, expression of GPR109A, a niacin receptor, which has anti-inflammatory activity in the retinal pigment epithelium, is increased in diabetic mouse and human retinas, which might suggest therapeutic potential . However, there are as yet no clinical data to support these hypotheses. Novel approaches are also warranted.
The R3i believe that optimizing the control of cardiovascular risk factors is critical to reducing the residual risk of diabetes-related microvascular complications in patients with type 2 diabetes. In this context, management of atherogenic dyslipidemia, a key driver of cardiovascular risk in this patient group, in addition to best standards of care, is relevant as supported by evidence from the REALIST-Micro study . In support, a large-scale study in a real-life setting suggested that improved lipid management, targeting HDL cholesterol and triglycerides in addition to non-HDL cholesterol, can reduce the risk of diabetic retinopathy, peripheral neuropathy, and/or nephropathy in type 2 diabetes patients . These data reinforce the importance of achieving appropriate lipid and lipoprotein levels as a key tenet of management to reduce both macro- and microvascular residual risk in patients with type 2 diabetes.
In terms of therapeutic targeting to reduce residual microvascular risk, the available data support a role for PPAR agonism, with the strongest evidence to date for fenofibrate, for slowing progression of early-stage diabetic retinopathy in patients with type 2 diabetes mellitus, as well as slowing progression of albuminuria. However, there remain unanswered questions as to the underlying mode of action, with both lipid- and non-lipid-related mechanisms implicated . Whether there are differential effects depending on the profile (alpha, gamma and/or delta), selectivity and potency of PPAR agonism clearly merits further investigation. Finally, whether the favorable microvascular benefits of PPARα agonism observed with fenofibrate extend to type 1 diabetes, a condition often characterized by lifelong hyperglycemia exposure, remains an open question.
Globally, we are facing a tsunami of type 2 diabetes, with prevalence estimates continually revised upwards. A major burden of diabetes lies in its chronic complications, both cardiovascular and microvascular. However, microvascular complications associated with type 2 diabetes are expected to account for much of the societal burden of disease, with progression to more advanced stages substantially increasing costs and disability and detrimentally affecting patient quality of life. This scenario highlights an urgent need for a renewed focus on approaches to prevent or delay progression of diabetic microvascular complications that occur despite best current standards of care.
The R3i believes that there are two key priorities to reducing the residual risk of diabetic complications in type 2 diabetes (Table 4). First, there is a need for optimal management of cardiometabolic risk factors, including atherogenic dyslipidemia, with improved lipid goal attainment. Second, the R3i believes that the consistent evidence for fenofibrate from the FIELD and ACCORD-Eye studies may merit consideration by clinicians involved in the care of patients with type 2 diabetes and retinopathy. The R3i believes that these data provide a clear rationale for a major prospective trial to investigate the role of fenofibrate, adjunctive to best standards of care, in preventing or slowing diabetic retinopathy in patients with type 2 diabetes. Collaboration between primary and secondary healthcare personnel on screening and preventive strategies targeted to the earliest stages of diabetic microvascular complications, in particular diabetic retinopathy, will help to drive through improvements in patient care. In conclusion, the R3i strongly believes that addressing both priorities is essential to reducing the substantial, disabling socioeconomic burden associated with the residual risk of diabetes-related chronic microvascular complications in type 2 diabetes.
Table 4: Recommendations of the R3i to reduce the residual risk of diabetesrelated microvascular complications in patients with type 2 diabetes.
MPH, JD and JCF researched data and prepared the initial draft manuscript. All authors were involved in the review of the manuscript and all approved the final manuscript. MPH takes responsibility for the content of the article.
The R3i is a non-profit academic organization which currently receives unrestricted educational grants from Abbott, Kowa and Roche. These grantors had no role in the design, preparation or review of this manuscript.
Conflicts of interest
P Amarenco (PA) has received research grants from Pfizer, Sanofi, Bristol- Myers-Squibb, Merck, AstraZeneca, Boehringer Ingelheim and the French government; and honoraria for lectures/consultancy from Pfizer, Sanofi, Bristol- Myers-Squibb, Merck, AstraZeneca, Boehringer Ingelheim, Bayer, Daiichi Sankyo, Lundbeck, Edwards, Boston Scientific, Kowa, and St-Jude Medical.
P Barter (PB) has received research grants from Merck and Pfizer; honoraria for consulting from Amgen, AstraZeneca, ISIS, Kowa, Merck, Novartis, Pfizer and Roche; and honoraria as a member of Advisory Boards from AstraZeneca, CSL, Kowa, Lilly, Merck, Novartis, Pfizer and Roche.
J Betteridge (JB) has received honoraria for advisory boards and lectures from MSD, Pfizer, AstraZeneca, Kowa, Janssen, Amgen, Takeda and Sanofi.
E Bruckert (EB) has received research funding from GlaxoSmithKline, MSD, Genzyme, Sanofi, Aegerion and Montreal University; and honoraria for consulting/ presentation from AstraZeneca, Genfit, Genzyme, MSD, Pfizer, Sanofi, Servier, AMT, Merck, Lilly, Novo-Nordisk, Pfizer and Aegerion.
MJ Chapman has received lecture honoraria, consultancy fees, or research funding from Aegerion, Amgen, AstraZeneca, Danone, Genzyme, Hoffman-La Roche, Kowa, Merck/Schering Plough, Pfi zer, Sanofi -Aventis/Regeneron, and Unilever.
A Cuevas (AC) has served on advisory boards for MSD and Amgen, and has received honoraria for lectures from MSD and Sanofi.
J Davignon (JD) has received honoraria for consultancy or as a scientific advisor for Abbott (Solvay), Acasti Pharma, Amgen, AstraZeneca, Anthera, Genzyme, McCain, Merck, Pfizer, Pharmena (Cortria), Regeneron-Sanofi, Roche and Valeant; and for participation in clinical trials for Amgen, Cortria, Genzyme, Merck, Pfizer and Regeneron-Sanofi. He has also received honoraria as a member of the Speakers bureau for the International Atherosclerosis Society. He is a Board Member for the Consortium Québecois sur la Découverte du Médicament (CQDM), and the Residual Risk Reduction Initiative Foundation.
E Ferrannini (EF) has received honoraria for speakers bureau/advisory boards from MDS, Halozyme, GlaxoSmithKline, Bristol-Myers-Squibb /AstraZeneca, Eli Lilly & Co., Novartis, Daiichi Sankyo and Sanofi. He has received research grant support from Eli Lilly & Co and Boehringer Ingelheim.
M Farnier (MF) has received grants, consulting fees and/or honoraria for lectures for Abbott, Amgen, Boehringer Ingelheim, Genzyme, Kowa, Merck and Co., Novartis, Pfizer, Recordati, Roche, Sanofi-Aventis and Bristol-Myers-Squibb.
P Fioretto (PF) has received honoraria for lectures from Abbott, Bristol-Myers- Squibb, AstraZeneca, Boehringer and Lilly.
J-C Fruchart (JCF) has received honoraria as a consultant for SMB laboratories, McCain and Kowa Co. Ltd. He is President of the Residual Risk Reduction Initiative.
J Genest (JG) has received research funding from Amgen, Lilly and Merck and honoraria as a member of Speaker’s bureau/advisory boards from Merck, Amgen, Sanofi and Aegerion.
HN Ginsberg (HNG) has received research funds from Sanofi-Regeneron, Amgen, Sanofi-Genzyme, Merck and consulting honoraria from Sanofi-Regeneron, Amgen, Sanofi-Genzyme, Merck, Bristol-Myers-Squibb, AstraZeneca, Pfizer, Kowa, Janssen and Boehringer Ingelheim.
AM Gotto (AMG) is on the board of Directors for Aegerion and Arisaph; has been a consultant for AstraZeneca, Janssen, Kowa, Merck, Pfizer and Roche; and has served on advisory boards for DuPont and Vatera Capital.
MP Hermans (MPH) has served on an advisory panel and/or received speaker’s honoraria or travel/research grants from Abbott, Amgen, AstraZeneca, Boehringer, Bristol-Myers-Squibb, Boehringer Ingelheim, GlaxoSmithKline, Janssen, Eli Lilly, LifeScan, Menarini, Merck, Novartis, Novo Nordisk, Roche, Sanofi and Takeda.
T Kodama (TK) has received honoraria as a consultant for Kowa Co.Ltd. and received research funding from Kowa Co. Ltd.
M Krempf (MK) has received honoraria for lectures from Astra Zeneca, MSD, Bristol-Myers-Squibb and Sanofi.
J Millan Nuñez-Cortes (JMN-C) has received honoraria as a member of Advisory Boards from Abbott, AstraZeneca, MSD, Pfizer and Sanofi; and for educational activities from Abbott, AstraZeneca and MSD.
H Ogawa (HO) has received honoraria for consulting from Amgen, GlaxoSmithKline and Novartis; and honoraria for lectures from AstraZeneca, Bayer, Boehringer lngelheim, Daiichi Sankyo, Mitsubishi Tanabe, MSD, Pfizer, Sanofi and Takeda. He has received research/scholarship grants from Bayer, Daiichi Sankyo, AstraZeneca, Astellas, Takeda, Mitsubishi Tanabe, Boehringer lngelheim, MSD and Pfizer.
J Plutzky (JP) has received research grants from GlaxoSmithKline and Bristol-Myers-Squibb; and honoraria for consultancy from Amylin Pharmaceuticals, AstraZeneca, Bristol-Myers-Squibb, Genzyme, GlaxoSmithKline, Eli Lilly, Janssen, Mesoblast, Merck, NovoNordisk, Pfizer, Roche/Genentech, Takeda and Vivus.
D Rader (DR) has received honoraria for consulting from Merck, Pfizer, Eli Lilly, Sanofi, Amgen, Novartis, Omthera, Aegerion and CSL.
Z Reiner (ZR) has received honoraria for lectures and advisory boards from Abbott, AstraZeneca and Sanofi.
R Santos (RS) has received honoraria for consulting and/or speaking from Astra Zeneca, Abbott, Biolab, Merck, Bristol Myers Squibb, Roche, Pfizer, Amgen, Aegerion, Boehringer Ingelheim, Sanofi, Genzyme and Nestle.
A Tall (AT) has received honoraria for lectures and advisory boards from MSD, Eli Lilly, Roche, Amgen, Arisaph and CSL.
L Tokgozoglu (LT) has received honoraria for lectures and advisory boards from Abbott, Actelion, AstraZeneca, Bayer, Boehringer Ingelheim, Daiichi Sankyo, Kowa, MSD, Novartis, Pfizer, Roche, Sanofi and Servier.
PP Toth (PPT) has received honoraria as a member of Speakers bureau for Amarin, AstraZeneca, GlaxoSmithKline, Kowa, Merck; and for consultancy for Amgen, AstraZeneca, Atherotech, Boehringer Ingelheim, Kowa, Liposcience and Merck.
P Valensi (PV) has given lectures and/or been a consultant for Abbott, MSD and Kowa.
C Wanner (CW) has received honoraria for lectures and travel support from Astellas, Merck and Pfizer.
A Zambon (AZ) has received speaker honoraria from Abbott, AstraZeneca, Roche and Amgen.
P Zimmet (PZ) has received travel funding from Fournier
K Al-Rubeaan (KA-R), G Assmann (GA), Y Matsuzawa (YM), C Calvo Monfil (CCM), D Hu (DH),T Kadowaki (TK), S Sadikot (SS), E Shlyakhto (ES), P Sritara (PS), R Sy (RS), CE Tan (CET) and JR Zhu (JRZ) report no competing interests.